NASDAQ:CELC Celcuity (CELC) Stock Forecast, Price & News $9.80 +0.23 (+2.40%) (As of 11:28 AM ET) Add Compare Share Share Today's Range$9.51▼$10.1450-Day Range$8.96▼$10.7552-Week Range$7.50▼$14.40Volume6,042 shsAverage Volume76,624 shsMarket Capitalization$216.48 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Celcuity MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside161.2% Upside$25.00 Price TargetShort InterestBearish26.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingSelling Shares$6,194 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.77) to ($2.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector608th out of 961 stocksMedical Laboratories Industry15th out of 23 stocks 3.5 Analyst's Opinion Consensus RatingCelcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.00, Celcuity has a forecasted upside of 161.2% from its current price of $9.57.Amount of Analyst CoverageCelcuity has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted26.07% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 29.1, which indicates bearish sentiment.Change versus previous monthShort interest in Celcuity has recently increased by 2.55%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELC. Previous Next 1.8 News and Social Media Coverage News SentimentCelcuity has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Celcuity this week, compared to 1 article on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,194.00 in company stock.Percentage Held by Insiders24.29% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Celcuity are expected to grow in the coming year, from ($2.77) to ($2.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Celcuity (NASDAQ:CELC) StockCelcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Read More CELC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELC Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comCelcuity (NASDAQ:CELC) Stock Rating Reaffirmed by Needham & Company LLCSeptember 14, 2023 | markets.businessinsider.comWill Celcuity's VIKTORIA-1 Hit The Target?September 26, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 7, 2023 | finance.yahoo.comCelcuity to Host Virtual Science Day for InvestorsAugust 23, 2023 | finanznachrichten.deCelcuity Inc.: Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement withAugust 23, 2023 | markets.businessinsider.comCelcuity (CELC) Has a New Rating from Craig-HallumAugust 22, 2023 | finance.yahoo.comCelcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate CancerAugust 22, 2023 | finance.yahoo.comCelcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical TrialSeptember 26, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 11, 2023 | finance.yahoo.comQ2 2023 Celcuity Inc Earnings CallAugust 10, 2023 | msn.comBRCC GAAP EPS of -$0.07 in-line, revenue of $91.9M beats by $1.15MAugust 10, 2023 | finance.yahoo.comCelcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesAugust 3, 2023 | finance.yahoo.comCelcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference CallJuly 31, 2023 | finance.yahoo.comCelcuity to Participate in the BTIG Virtual Biotechnology Conference 2023July 27, 2023 | finance.yahoo.comCelcuity Inc. (NASDAQ:CELC) stock most popular amongst individual investors who own 23%, while private equity firms hold 22%June 20, 2023 | finanznachrichten.deCelcuity Inc.: Celcuity Set to Join Russell 2000 and 3000 IndexesJune 20, 2023 | finance.yahoo.comCelcuity Set to Join Russell 2000 and 3000 IndexesMay 24, 2023 | finance.yahoo.comInsiders of Celcuity Getting Good Value On Their US$1.6m InvestmentMay 16, 2023 | msn.comNeedham Reiterates Celcuity (CELC) Buy RecommendationMay 16, 2023 | finance.yahoo.comQ1 2023 Celcuity Inc Earnings CallMay 15, 2023 | finance.yahoo.comCelcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesMay 15, 2023 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Celcuity (CELC)May 13, 2023 | marketwatch.comCelcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naive Patients at the 2023 ESMO Breast Cancer Annual CongressMay 12, 2023 | msn.comA Preview Of Celcuity's EarningsMay 12, 2023 | msn.comCelcuity gedatolisib combo shows promise in phase 1b trial in breast cancer patientsMay 8, 2023 | finance.yahoo.comCelcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference CallMay 8, 2023 | finance.yahoo.comCelcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual CongressSee More Headlines Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address CELC Company Calendar Last Earnings8/10/2023Today9/26/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CELC CUSIPN/A CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees45Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+161.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.73% Return on Assets-35.04% Debt Debt-to-Equity Ratio0.33 Current Ratio21.58 Quick Ratio21.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book1.55Miscellaneous Outstanding Shares22,090,000Free Float16,724,000Market Cap$211.40 million OptionableNot Optionable Beta0.60 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Brian F. Sullivan (Age 61)Co-Founder, Chairman & CEO Comp: $105.77kDr. Lance G. Laing Ph.D. (Age 61)Co-Founder, Chief Science Officer, VP, Sec. & Director Comp: $325.38kMs. Vicky Hahne (Age 57)Chief Financial Officer Comp: $210kDr. John R. MacDonald Dabt (Age 68)Ph., Ph.D., Sr. VP of R&D Ms. Sheri SmithActing Head of Clinical OperationsMr. Igor Gorbatchevsky M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsInvitaeNYSE:NVTABiodesixNASDAQ:BDSXGenetronNASDAQ:GTHMDxHealthNASDAQ:MDXHEnzo BiochemNYSE:ENZView All CompetitorsInsiders & InstitutionsBarclays PLCBought 3,451 shares on 9/21/2023Ownership: 0.016%Richard E BullerSold 350 sharesTotal: $3,248.00 ($9.28/share)Richard E BullerSold 300 sharesTotal: $2,946.00 ($9.82/share)California State Teachers Retirement SystemBought 5,732 shares on 8/21/2023Ownership: 0.026%Royal Bank of CanadaBought 2,424 shares on 8/15/2023Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions CELC Stock - Frequently Asked Questions Should I buy or sell Celcuity stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares. View CELC analyst ratings or view top-rated stocks. What is Celcuity's stock price forecast for 2023? 1 equities research analysts have issued 1 year target prices for Celcuity's stock. Their CELC share price forecasts range from $25.00 to $25.00. On average, they anticipate the company's share price to reach $25.00 in the next year. This suggests a possible upside of 161.2% from the stock's current price. View analysts price targets for CELC or view top-rated stocks among Wall Street analysts. How have CELC shares performed in 2023? Celcuity's stock was trading at $14.01 on January 1st, 2023. Since then, CELC shares have decreased by 31.7% and is now trading at $9.57. View the best growth stocks for 2023 here. When is Celcuity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our CELC earnings forecast. How were Celcuity's earnings last quarter? Celcuity Inc. (NASDAQ:CELC) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.01. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID). When did Celcuity IPO? (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. What is Celcuity's stock symbol? Celcuity trades on the NASDAQ under the ticker symbol "CELC." Who are Celcuity's major shareholders? Celcuity's stock is owned by a number of retail and institutional investors. Top institutional investors include Commodore Capital LP (6.66%), BlackRock Inc. (4.21%), Captrust Financial Advisors (2.57%), Geode Capital Management LLC (1.36%), State Street Corp (1.21%) and Northern Trust Corp (0.84%). Insiders that own company stock include Brian F Sullivan, Richard E Buller and Richard Nigon. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celcuity's stock price today? One share of CELC stock can currently be purchased for approximately $9.57. How much money does Celcuity make? Celcuity (NASDAQ:CELC) has a market capitalization of $211.40 million. The company earns $-40,370,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. How can I contact Celcuity? Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The official website for the company is www.celcuity.com. The company can be reached via phone at (763) 392-0767. This page (NASDAQ:CELC) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.